Results 41 to 50 of about 23,388 (179)

Case Series of Patients With FGFR1‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options

Clinical Endocrinology, EarlyView.
ABSTRACT Pheochromocytoma and paraganglioma (together PPGL) are tumours with a high degree of heritability. Genetic landscape is divided into three clusters, cluster 1 (Krebs/pseudohypoxia signalling pathway), cluster 2 (kinase signalling pathway) and cluster 3 (Wnt signalling pathway).
Sakshi Jhawar, Abhishek Jha, Sara Talvacchio, Junne Kamihara, Jaydira Del Rivero, Karel Pacak   +5 more
wiley   +1 more source

Approach to the Management of Gastrointestinal Manifestations in Patients With Phaeochromocytoma and Paraganglioma

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Managing gastrointestinal symptoms in patients with phaeochromocytoma and paraganglioma (PPGL) is challenging due to the risk of catecholaminergic crisis with many commonly prescribed medications, especially in functional tumours.
Monica Majumder, Cherie Chiang, Grace Kong, Michael Michael, Nirupa Sachithanandan, Emma Boehm   +5 more
wiley   +1 more source

Functional paraganglioma of the bladder: Both radiographic‐negative and laboratory‐negative case

IJU Case Reports, 2019
Introduction Paraganglioma has been determined to be an extra‐adrenal pheochromocytoma. Paraganglioma of the bladder is a rare entity, accounting for 0.06% of all bladder tumors.
Rumiko Sugimura, Takashi Kawahara, Go Noguchi, Daiji Takamoto, Koji Izumi, Jun‐ichi Teranishi, Yasuhide Miyoshi, Masahiro Yao, Masako Otani, Hiroji Uemura   +9 more
doaj   +1 more source

Genetic Testing Referral Rates for Pheochromocytoma and Paraganglioma in an Academic Tertiary Centre

Clinical Endocrinology, EarlyView.
ABSTRACT Background Clinical guidelines recommend genetic counselling for all patients with pheochromocytoma or paraganglioma (PPGL). Barriers to accessing genetics evaluation are incompletely understood. The objective of this study was to identify individual‐ and provider‐level barriers to genetic testing.
Brian Ruhle, Na Eun Kim, Sang Ngo, Elena G. Hughes, Dipti P. Sajed, Run Yu, James X. Wu, Michael W. Yeh, Masha J. Livhits   +8 more
wiley   +1 more source

Choroidal Paraganglioma with Metastases to the Fellow Eye

Case Reports in Ophthalmology, 2013
Purpose: To report a case of a paraganglioma in the right eye with metastatic disease in the fellow eye 3 years later. Methods: A 70-year-old man presented with a painful amblyopic right eye; rubeosis iridis and a large choroidal tumor were found.
Rita Van Ginderdeuren, Guy S. Missotten, Joost van den Oord   +2 more
doaj   +1 more source

Detection of severe hypertension in a patient with neurofibromatosis type 1 during anesthesia induction: a case report

Journal of Medical Case Reports, 2019
Background Neurofibromatosis type 1 has a higher prevalence of pheochromocytoma and paraganglioma than the general population: 1.0–5.7% versus 0.2–0.6%.
Juan Wang, Guohua Wei, Zhongyun Wang, He Huang   +3 more
doaj   +1 more source

Robot assisted laparoscopic excision of a paraganglioma: new therapeutic approach

International Brazilian Journal of Urology, 2014
The Paraganglioma is the most common extra-adrenal pheochromocytoma arising from neural crest (1) (It will better to write: The paraganglioma is an extra-adrenal pheocromocytoma arising from the neural crest. 10% of pheocromocytomas are extra-adrenal and
G. Cochetti, E. Cottini, F. Barillaro, E. Lepri, A. Boni, S. Pohja, E. Mearini   +6 more
doaj   +1 more source

Bladder paraganglioma: A case of acute respiratory distress syndrome triggered by large bladder tumor transurethral resection with mild symptoms and atypical imaging

IJU Case Reports, 2023
Introduction Bladder paraganglioma is exceedingly rare, accounting for
Toshifumi Takahashi, Tatsuya Hazama, Hideto Ota, Yuya Yamada, Masakazu Nakashima, Masahiro Tamaki, Noriyuki Ito   +6 more
doaj   +1 more source

PI5P4K inhibitors: promising opportunities and challenges

The FEBS Journal, EarlyView.
Developing inhibitors is like climbing a steep, challenging mountain. PI5P4K inhibitors hold significant promise for the treatment of cancer, immune disorders, and neurological diseases. However, the path to success is fraught with hurdles, and researchers are therefore required to apply their expertise to overcome critical “checkpoints.” While some ...
Koh Takeuchi, Lisa Nagase, Shun Kageyama, Hirotaka Kanoh, Masashi Oshima, Aki Ogawa‐Iio, Yoshiki Ikeda, Yuki Fujii, Sei Kondo, Natsuki Osaka, Takeshi Masuda, Tsukasa Ishihara, Yoshikazu Nakamura, Yoshihisa Hirota, Takehiko Sasaki, Toshiya Senda, Atsuo T. Sasaki   +16 more
wiley   +1 more source

The G protein‐coupled receptor GPR89A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells

The FEBS Journal, EarlyView.
A genome‐wide CRISPR‐Cas9‐based genetic screen in cisplatin‐resistant NSCLC cells revealed 63 potential candidate genes for overcoming cisplatin resistance, including GPR89A. GPR89A, localised in the Golgi, modulates voltage‐gated anion channel activity and is involved in intracellular pH reduction.
Hale Guler Kara, Eda Dogan, Vildan Bozok, Cagdas Aktan, Ece Cakiroglu, Zuhal Eroglu, Duygu Aygunes Jafari, Kemal Sami Korkmaz, Serif Senturk, Buket Kosova   +9 more
wiley   +1 more source